CoChat
Sign Up
Cited by 143Amyotrophic Lateral Sclerosis ResearchNuclear Structure and FunctionHereditary Neurological Disorders

Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS

Open access
Coyne, Alyssa N., Baskerville, Victoria, Zaepfel, Benjamin L., Dickson, Dennis W., Rigo, Frank, Bennett, Frank, Lusk, C. Patrick, Rothstein, Jeffrey D.·2021·Science Translational Medicine
DOI 10.1126/scitranslmed.abe1923PMC PMC9022198
Open this paper in CoChat — free account

Abstract

Nuclear accumulation of CHMP7 leads to multiple cellular pathologies that can be mitigated via CHMP7 ASOs in familial and sporadic ALS iPSNs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.abe1923

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Deficiencies in nucleocytoplasmic transport machinery are increasingly implicated as a potential contributing factor to ALS pathology.

    “Although the origins of TDP43 mislocalization are unclear, deficiencies in nucleocytoplasmic transport machinery are increasingly implicated as a potential contributing factor to ALS pathology (8).”

    From Nemo-like kinase disrupts nuclear import and drives TDP43 mislocalization in ALS (2025) · cites this paper as [8]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 53

  1. [2]Taylor JP, Brown RH Jr., Cleveland DW, Decoding ALS: From genes to mechanism. Nature 539, 197– 206 (2016). 27830784 PMC5585017
  2. [3]Kim G, Gautier O, Tassoni-Tsuchida E, Ma XR, Gitler AD, ALS genetics: Gains, losses, and implications for future therapies. Neuron 108, 822– 842 (2020). 32931756 PMC7736125
  3. [4]Sances S, Bruijn LI, Chandran S, Eggan K, Ho R, Klim JR, Livesey MR, Lowry E, Macklis JD, Rushton D, Sadegh C, Sareen D, Wichterle H, Zhang S-C, Svendsen CN, Modeling ALS with motor neurons derived from human induced pluripotent stem cells. Nat. Neurosci 19, 542– 553 (2016). 27021939 PMC5015775
  4. [5]Zhang X, Hu D, Shang Y, Qi X, Using induced pluripotent stem cell neuronal models to study neurodegenerative diseases. Biochim. Biophys. Acta Mol. Basis Dis 1866, 165431 (2019). 30898538 PMC6751032
  5. [6]Donnelly CJ, Zhang P-W, Pham JT, Haeusler AR, Mistry NA, Vidensky S, Daley EL, Poth EM, Hoover B, Fines DM, Maragakis N, Tienari PJ, Petrucelli L, Traynor BJ, Wang J, Rigo F, Bennett CF, Blackshaw S, Sattler R, Rothstein JD, RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron 80, 415– 428 (2013). 24139042 PMC4098943
  6. [7]Gendron TF, Chew J, Stankowski JN, Hayes LR, Zhang Y-J, Prudencio M, Carlomagno Y, Daughrity LM, Jansen-West K, Perkerson EA, O’Raw A, Cook C, Pregent L, Belzil V, van Blitterswijk M, Tabassian LJ, Lee CW, Yue M, Tong J, Song Y, Castanedes-Casey M, Rousseau L, Phillips V, Dickson DW, Rademakers R, Fryer JD, Rush BK, Pedraza O, Caputo AM, Desaro P, Palmucci C, Robertson A, Heckman MG, Diehl NN, Wiggs E, Tierney M, Braun L, Farren J, Lacomis D, Ladha S, Fournier CN, McCluskey LF, Elman LB, Toledo JB, McBride JD, Tiloca C, Morelli C, Poletti B, Solca F, Prelle A, Wuu J, Jockel-Balsarotti J, Rigo F, Ambrose C, Datta A, Yang W, Raitcheva D, Antognetti G, McCampbell A, van Swieten JC, Miller BL, Boxer AL, Brown RH, Bowser R, Miller TM, Trojanowski JQ, Grossman M, Berry JD, Hu WT, Ratti A, Traynor BJ, Disney MD, Benatar M, Silani V, Glass JD, Floeter MK, Rothstein JD, Boylan KB, Petrucelli L, Poly(GP) proteins are a useful pharmacodynamic marker forC9ORF72-associated amyotrophic lateral sclerosis. Sci. Transl. Med 9, eaai7866 (2017). 28356511 PMC5576451
  7. [8]Coyne AN, Zaepfel BL, Hayes L, Fitchman B, Salzberg Y, Luo E-C, Bowen K, Trost H, Aigner S, Rigo F, Yeo GW, Harel A, Svendsen CN, Sareen D, Rothstein JD, G4C2 repeat RNA initiates a POM121-mediated reduction in specific nucleoporins in C9orf72 ALS/FTD. Neuron 107, 1124– 1140.e11 (2020). 32673563 PMC8077944
  8. [9]Beck M, Hurt E, The nuclear pore complex: Understanding its function through structural insight. Nat. Rev. Mol. Cell Biol 18, 73– 89 (2017). 27999437
  9. [10]Lin DH, Hoelz A, The structure of the nuclear pore complex (an update). Annu. Rev. Biochem 88, 725– 783 (2019). 30883195 PMC6588426
  10. [11]Raices M, D’Angelo MA, Nuclear pore complex composition: A new regulator of tissue-specific and developmental functions. Nat. Rev. Mol. Cell Biol 13, 687– 699 (2012). 23090414
  11. [12]Raices M, D’Angelo MA, Nuclear pore complexes and regulation of gene expression. Curr. Opin. Cell Biol 46, 26– 32 (2017). 28088069 PMC5505778
  12. [13]Webster BM, Colombi P, Jager J, Lusk CP, Surveillance of nuclear pore complex assembly by ESCRT-III/Vps4. Cell 159, 388– 401 (2014). 25303532 PMC4194032
  13. [14]Thaller DJ, Allegretti M, Borah S, Ronchi P, Beck M, Lusk CP, An ESCRT-LEM protein surveillance system is poised to directly monitor the nuclear envelope and nuclear transport system. eLife 8, e45284 (2019). 30942170 PMC6461442
  14. [15]Webster BM, Thaller DJ, Jäger J, Ochmann SE, Borah S, Lusk CP, Chm7 and Heh1 collaborate to link nuclear pore complex quality control with nuclear envelope sealing. EMBO J. 35, 2447– 2467 (2016). 27733427 PMC5109239
  15. [16]Toyama BH, Drigo RAE, Lev-Ram V, Ramachandra R, Deerinck TJ, Lechene C, Ellisman MH, Hetzer MW, Visualization of long-lived proteins reveals age mosaicism within nuclei of postmitotic cells. J. Cell Biol 218, 433– 444 (2018). 30552100 PMC6363465
  16. [17]Lee CW, Wilfling F, Ronchi P, Allegretti M, Mosalaganti S, Jentsch S, Beck M, Pfander B, Selective autophagy degrades nuclear pore complexes. Nat. Cell Biol 22, 159– 166 (2020). 32029894
  17. [18]Tomioka Y, Kotani T, Kirisako H, Oikawa Y, Kimura Y, Hirano H, Ohsumi Y, Nakatogawa H, TORC1 inactivation stimulates autophagy of nucleoporin and nuclear pore complexes. J. Cell Biol 219, e201910063 (2020). 32453403 PMC7337488
  18. [19]Lusk CP, Ader NR, CHMPions of repair: Emerging perspectives on sensing and repairing the nuclear envelope barrier. Curr. Opin. Cell Biol 64, 25– 33 (2020). 32105978 PMC7371540
  19. [20]Robberecht W, Philips T, The changing scene of amyotrophic lateral sclerosis. Nat. Rev. Neurosci 14, 248– 264 (2013). 23463272
  20. [21]Maglione M, Sigrist SJ, Seeing the forest tree by tree: Super-resolution light microscopy meets the neurosciences. Nat. Neurosci 16, 790– 797 (2013). 23799471
  21. [22]Schermelleh L, Carlton PM, Haase S, Shao L, Winoto L, Kner P, Burke B, Cardoso MC, Agard DA, Gustafsson MGL, Leonhardt H, Sedat JW, Subdiffraction multicolor imaging of the nuclear periphery with 3D structured illumination microscopy. Science 320, 1332– 1336 (2008). 18535242 PMC2916659
  22. [24]Boeynaems S, Bogaert E, Van Damme P, Van Den Bosch L, Inside out: The role of nucleocytoplasmic transport in ALS and FTLD. Acta Neuropathol. 132, 159– 173 (2016). 27271576 PMC4947127
  23. [25]Hutten S, Dormann D, Nucleocytoplasmic transport defects in neurodegeneration-Cause or consequence? Semin. Cell Dev. Biol. 99, 151– 162 (2019). 31152789
  24. [26]Jovicic A, Paul III JW, Gitler AD, Nuclear transport dysfunction: A common theme in amyotrophic lateral sclerosis and frontotemporal dementia. J. Neurochem 138 (Suppl 1), 134– 144 (2016). 27087014
  25. [27]Kim HJ, Taylor JP, Lost in transportation: Nucleocytoplasmic transport defects in ALS and other neurodegenerative diseases. Neuron 96, 285– 297 (2017). 29024655 PMC5678982
  26. [28]Vietri M, Schultz SW, Bellanger A, Jones CM, Petersen LI, Raiborg C, Skarpen E, Pedurupillay CRJ, Kjos I, Kip E, Timmer R, Jain A, Collas P, Knorr RL, Grellscheid SN, Kusumaatmaja H, Brech A, Micci F, Stenmark H, Campsteijn C, Unrestrained ESCRT-III drives micronuclear catastrophe and chromosome fragmentation. Nat. Cell Biol 22, 856– 867 (2020). 32601372
  27. [29]Gu M, LaJoie D, Chen O-S, von Appen A, Ladinsky MS, Redd MJ, Nikolova L, Bjorkman PJ, Sundquist WI, Ullman KS, Frost A, LEM2 recruits CHMP7 for ESCRT-mediated nuclear envelope closure in fission yeast and human cells. Proc. Natl. Acad. Sci. U.S.A 114, E2166– E2175 (2017). 28242692 PMC5358359
  28. [30]Suk TR, Rousseaux MWC, The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol. Neurodegener 15, 45 (2020). 32799899 PMC7429473
  29. [31]Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JNS, Trujillo A, Pribadi M, Phillips JJ, Gaus SE, Hixson JD, Garcia PA, Rabinovici GD, Coppola G, Geschwind DH, Petrucelli L, Miller BL, Seeley WW, Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain J. Neurol 139, 3202– 3216 (2016). PMC5790143 27797809
  30. [32]Gao J, Wang L, Huntley ML, Perry G, Wang X, Pathomechanisms of TDP-43 in neurodegeneration. J. Neurochem 146, 7– 20 (2018). PMC6110993 29486049
  31. [33]Coyne AN, Zaepfel BL, Zarnescu DC, Failure to deliver and translate-new insights into RNA dysregulation in ALS. Front. Cell. Neurosci 11, 243 (2017). 28860970 PMC5562674
  32. [34]Melamed Z, López-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, Freyermuth F, Mahon MAM, Beccari MS, Artates JW, Ohkubo T, Rodriguez M, Lin N, Wu D, Bennett CF, Rigo F, Cruz SD, Ravits J, Lagier-Tourenne C, Cleveland DW, Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat. Neurosci 22, 180– 190 (2019). 30643298 PMC6348009
  33. [36]Klim JR, Williams LA, Limone F, Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, Burberry A, Steinbaugh MJ, Gamage KK, Kirchner R, Moccia R, Cassel SH, Chen K, Wainger BJ, Woolf CJ, Eggan K, ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat. Neurosci 22, 167– 179 (2019). 30643292 PMC7153761
  34. [39]Thammisetty SS, Pedragosa J, Weng YC, Calon F, Planas A, Kriz J, Age-related deregulation of TDP-43 after stroke enhances NF-κB-mediated inflammation and neuronal damage. J. Neuroinflammation 15, 312 (2018). 30413172 PMC6230239
  35. [42]Melchior F, Ran GTPase cycle: One mechanism—Two functions. Curr. Biol 11, R257– R260 (2001). 11413013
  36. [43]Chou CC, Zhang Y, Umoh ME, Vaughan SW, Lorenzini I, Liu F, Sayegh M, Donlin-Asp PG, Chen YH, Duong DM, Seyfried NT, Powers MA, Kukar T, Hales CM, Gearing M, Cairns NJ, Boylan KB, Dickson DW, Rademakers R, Zhang Y-J, Petrucelli L, Sattler R, Zarnescu DC, Glass JD, Rossoll W, TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat. Neurosci 21, 228– 239 (2018). 29311743 PMC5800968
  37. [44]Eftekharzadeh B, Daigle JG, Kapinos LE, Coyne A, Schiantarelli J, Carlomagno Y, Cook C, Miller SJ, Dujardin S, Amaral AS, Grima JC, Bennett RE, Tepper K, De Ture M, Vanderburg CR, Corjuc BT, De Vos SL, Gonzalez JA, Chew J, Vidensky S, Gage FH, Mertens J, Troncoso J, Mandelkow E, Salvatella X, Lim RYH, Petrucelli L, Wegmann S, Rothstein JD, Hyman BT, Tau protein disrupts nucleocytoplasmic transport in Alzheimer’s disease. Neuron 99, 925– 940.e7 (2018). 30189209 PMC6240334
  38. [45]Grima JC, Daigle JG, Arbez N, Cunningham KC, Zhang K, Ochaba J, Geater C, Morozko E, Stocksdale J, Glatzer JC, Pham JT, Ahmed I, Peng Q, Wadhwa H, Pletnikova O, Troncoso JC, Duan W, Snyder SH, Ranum LPW, Thompson LM, Lloyd TE, Ross CA, Rothstein JD, Mutant huntingtin disrupts the nuclear pore complex. Neuron 94, 93– 107.e6 (2017). 28384479 PMC5595097
  39. [46]Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, Gupta S, Thomas MA, Hong I, Chiu SL, Huganir RL, Ostrow LW, Matunis MJ, Wang J, Sattler R, Lloyd TE, Rothstein JD, The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 525, 56– 61 (2015). 26308891 PMC4800742
  40. [47]Chew J, Cook C, Gendron TF, Jansen-West K, del Rosso G, Daughrity LM, Castanedes-Casey M, Kurti A, Stankowski JN, Disney MD, Rothstein JD, Dickson DW, Fryer JD, Zhang Y-J, Petrucelli L, Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Mol. Neurodegener 14, 9 (2019). 30767771 PMC6377782
  41. [48]Zhang YJ, Gendron TF, Ebbert MTW, O’Raw AD, Yue M, Jansen-West K, Zhang X, Prudencio M, Chew J, Cook CN, Daughrity LM, Tong J, Song Y, Pickles SR, Castanedes-Casey M, Kurti A, Rademakers R, Oskarsson B, Dickson DW, Hu W, Gitler AD, Fryer JD, Petrucelli L, Poly(GR) impairs protein translation and stress granule dynamics in C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis. Nat. Med 24, 1136– 1142 (2018). 29942091 PMC6520050
  42. [49]Zhang YJ, Gendron TF, Grima JC, Sasaguri H, Jansen-West K, Xu Y-F, Katzman RB, Gass J, Murray ME, Shinohara M, Lin W-L, Garrett A, Stankowski JN, Daughrity L, Tong J, Perkerson EA, Yue M, Chew J, Castanedes-Casey M, Kurti A, Wang ZS, Liesinger AM, Baker JD, Jiang J, Lagier-Tourenne C, Edbauer D, Cleveland DW, Rademakers R, Boylan KB, Bu G, Link CD, Dickey CA, Rothstein JD, Dickson DW, Fryer JD, Petrucelli L, C9ORF72 poly(GA) aggregates sequester and impair HR23 and nucleocytoplasmic transport proteins. Nat. Neurosci 19, 668– 677 (2016). 26998601 PMC5138863
  43. [50]Zhang Y-J, Guo L, Gonzales PK, Gendron TF, Wu Y, Jansen-West K, O’Raw AD, Pickles SR, Prudencio M, Carlomagno Y, Gachechiladze MA, Ludwig C, Tian R, Chew J, De Ture M, Lin W-L, Tong J, Daughrity LM, Yue M, Song Y, Andersen JW, Castanedes-Casey M, Kurti A, Datta A, Antognetti G, Campbell AM, Rademakers R, Oskarsson B, Dickson DW, Kampmann M, Ward ME, Fryer JD, Link CD, Shorter J, Petrucelli L, Heterochromatin anomalies and double-stranded RNA accumulation underlie C9orf72 poly(PR) toxicity. Science 363, eaav2606 (2019). 30765536 PMC6524780
  44. [51]Thevathasan JV, Kahnwald M, Cieśliński K, Hoess P, Peneti SK, Reitberger M, Heid D, Kasuba KC, Hoerner SJ, Li Y, Wu Y-L, Mund M, Matti U, Pereira PM, Henriques R, Nijmeijer B, Kueblbeck M, Sabinina VJ, Ellenberg J, Ries J, Nuclear pores as versatile reference standards for quantitative superresolution microscopy. Nat. Methods 16, 1045– 1053 (2019). 31562488 PMC6768092
  45. [52]McCullough J, Frost A, Sundquist WI, Structures, functions, and dynamics of ESCRT-III/Vps4 membrane remodeling and fission complexes. Annu. Rev. Cell Dev. Biol 34, 85– 109 (2018). 30095293 PMC6241870
  46. [55]Chang XL, Tan MS, Tan L, Yu JT, The role of TDP-43 in Alzheimer’s disease. Mol. Neurobiol 53, 3349– 3359 (2016). 26081142
  47. [56]Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, Mc Cluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM-Y, Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130– 133 (2006). 17023659
  48. [57]Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, Petrucelli L, Senjem ML, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Jack CR Jr., Parisi JE, Petersen RC, Dickson DW, TDP-43 is a key player in the clinical features associated with Alzheimer’s disease. Acta Neuropathol 127, 811– 824 (2014). 24659241 PMC4172544
  49. [58]Robinson JL, Lee EB, Xie SX, Rennert L, Suh E-R, Bredenberg C, Caswell C, van Deerlin VM, Yan N, Yousef A, Hurtig HI, Siderowf A, Grossman M, McMillan CT, Miller B, Duda JE, Irwin DJ, Wolk D, Elman L, McCluskey L, Chen-Plotkin A, Weintraub D, Arnold SE, Brettschneider J, Lee VM-Y, Trojanowski JQ, Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain J. Neurol 141, 2181– 2193 (2018). PMC6022546 29878075
  50. [59]Vossel KA, Bien-Ly N, Bernardo A, Rascovsky K, Karydas A, Rabinovici GD, Sidhu M, Huang EJ, Miller BL, Huang Y, Seeley WW, ApoE and TDP-43 neuropathology in two siblings with familial FTLD-motor neuron disease. Neurocase 19, 295– 301 (2013). 22512241 PMC3655113
  51. [60]Wennberg AM, Tosakulwong N, Lesnick TG, Murray ME, Whitwell JL, Liesinger AM, Petrucelli L, Boeve BF, Parisi JE, Knopman DS, Petersen RC, Dickson DW, Josephs KA, Association of apolipoprotein E ε4 with transactive response DNA-binding protein 43. JAMA Neurol. 75, 1347– 1354 (2018). 30422173 PMC6248121
  52. [61]Yang HS, Yu L, White CC, Chibnik LB, Chhatwal JP, Sperling RA, Bennett DA, Schneider JA, de Jager PL, Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE ε4 haplotype status: A community-based cohort study. Lancet Neurol. 17, 773– 781 (2018). 30093249 PMC6154505
  53. [62]Sennepin AD, Charpentier S, Normand T, Sarré C, Legrand A, Mollet LM, Multiple reprobing of Western blots after inactivation of peroxidase activity by its substrate, hydrogen peroxide. Anal. Biochem 393, 129– 131 (2009). 19523435

Cited by

Sorted by citations

Authors
Coyne, A. N., Baskerville, V., Zaepfel, B. L., Dickson, D. W., Rigo, F., Bennett, F., Lusk, C. P., & Rothstein, J. D.
Affiliations
  • Mayo Clinic (US)
  • Johns Hopkins University (US)
Corresponding author
  • Coyne, Alyssa N.
  • Rothstein, Jeffrey D.
ORCID
Venue
Science Translational Medicine
Publisher
American Association for the Advancement of Science (AAAS)
Published
2021-07-28
Volume
13
Issue
604
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
DOI
10.1126/scitranslmed.abe1923
PMC
PMC9022198
OpenAlex
W3186516181
Cited by
143
References
9
Citations by year
2026: 22 · 2025: 36 · 2024: 23 · 2023: 27 · 2022: 28 · 2021: 6 · 2019: 1
FWCI
10.05
Type
journal article
Language
en
Open access
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (AG057623;NS099114;NS094239, P01NS099114, U54NS091046, R01NS094239, R01NS122236)
  • U.S. Department of Defense
  • Robert Packard Center for ALS Research, Johns Hopkins University
  • Amyotrophic Lateral Sclerosis Association
  • Chan Zuckerberg Initiative
  • ALS Finding A Cure
  • Muscular Dystrophy Association
  • Fidelity Foundation
Topics
  • Health Sciences › Medicine › Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Structure and Function
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
Keywords
CHMP7, nuclear pore complex, amyotrophic lateral sclerosis, familial ALS, sporadic ALS, nuclear export inhibition, Ran GTPase, motor cortex, glutamate-induced neuronal death, therapeutic target
MeSH terms
C9orf72 Protein, Amyotrophic Lateral Sclerosis, DNA-Binding Proteins, Humans, Nuclear Pore, Endosomal Sorting Complexes Required for Transport, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review